Articles by Louis Garguilo

  1. A Cost Measurement Pharma Can Live With (CROs/CMOs, Too) 6/2/2015

    Sometimes one finds help in unusual places. This might be one of those times for Pharma, and the place could be AdverseEvents. And Pharma can turn to a more usual partner — CROs/CMOs — to positively influence what AdverseEvents measures.

  2. CROs In A Business Exchange With Silicon Valley? 5/29/2015

    As an applied economic theoretic, by driving out inefficiencies from the current model used by researchers to find and contract with CROs, the Science Exchange should improve the business model for drug discovery. But will all parties — Pharma/Bio, CROs and individual researchers — benefit equally? 

  3. Corning A Force For Flow Reactors 3/20/2015

    On a morning in Shanghai when the air is anything but, Dr. Yi Jiang of Corning is crystal clear on his view of the biopharmaceutical industry’s transitioning from batch to advanced-flow reactors.

  4. Pfizer Acquires Hospira: Biosimilars Gain Full Pharma Acceptance 2/5/2015

    Just days after Outsourced Pharma’s in-depth, two-part article on Hospira and the role of biosimilars in global healthcare, and in which I asked Hospira’s Sumant Ramachandra whether he foresaw a future where a Pfizer comes to Hospira to work together on biosimilars, we have a definitive answer.

  5. Biosimilars Part 2: It's All About Dollars Now 2/2/2015

    Time to table the discussion on the science of replicating biologics. It’s all about dollars now. Part two of our look at biosimilars in the U.S.

  6. Biosimilars: A Brief Manifesto of Morality And Markets 1/26/2015

    As best I can describe it, here's an ideology for biosimilars in the U.S. healthcare system, from Sumant Ramachandra, executive and scientist at Hospira, Inc.

  7. A Global Forum For Outsourcing (With Simple Objectives) 9/24/2014

    Perhaps the best advice I’ve heard regarding industry conferences is twofold: first, make sure you attend, and second, keep your objectives for attending simple.

  8. A Trait For Quailty In John McKay's DNA 9/24/2014

    If you string together some of John McKay’s qualifications, they form what looks something like a strand of DNA from a new life form: CMQCQAQMS. And this particular gene would express a single trait: McKay knows quality like few others.

  9. Serial Entrepreneur Points To Initial Funding Sources For Biotechs 9/24/2014

    Kevin Judice lists himself on LinkedIn as “Entrepreneur.” Perhaps he has to; there just isn’t enough space to include the three companies he recently started and at which he concurrently is employed as CEO or CSO.

  10. Lean Six Sigma From An Outsourcing Industry Raconteur 8/29/2014

    Bikash Chatterjee knows all about Lean Six Sigma. He’ll share that wisdom with us at Outsourced Pharma West in San Francisco, November 11-12. However, you might not notice when he’s doing it.